Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: Phase I/II study

Cancer Chemotherapy and Pharmacology

Volumn 62, Issue 3, 2008, Pages 393-400

  Koensgen, Dominique ^a   Stengel, Dirk ^b   Belau, Antje ^c   Klare, Peter ^a   Oskay Oezcelik, Guelten ^a   Steck, Thomas ^d   Camara, Oumar ^e   Mustea, Alexander ^a   Sommer, Harald ^f   Coumbos, Alexandra ^a   Bogenrieder, Thomas ^g   Lichtenegger, Werner ^a   Sehouli, Jalid ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Center for Clinical Research   (Germany)

^c UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^d KLINIKUM CHEMNITZ   (Germany)

^e JENA UNIVERSITY HOSPITAL   (Germany)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^g GLAXOSMITHKLINE   (Germany)

Author keywords

Carboplatin; Chemotherapy; Platinum based combination; Platinum sensitive recurrent ovarian cancer; Topotecan

Indexed keywords

CARBOPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; SEROTONIN 3 ANTAGONIST; TOPOTECAN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TRANSFUSION; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE INTERVAL; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEMATOLOGIC DISEASE; HUMAN; LEUKOPENIA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SURVIVAL RATE; SURVIVAL TIME; THERAPY DELAY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PROSPECTIVE STUDIES; TOPOTECAN;

EID: 45749148248     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0617-2     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E et al (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106-130
2. Ozols RF, Bookman MA, Connolly DC et al (2004) Focus on epithelial ovarian cancer. Cancer Cell 5:19-24
3. Markmann M, Rothman R, Hakes T et al (1991) Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9:389-393
4. Gore ME, Fryatt I, Wiltshaw E et al (1990) Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 36:207-211
5. Parmar MK, Ledermann JA, Colombo N et al (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361(9375):2099-2106
6. du Bois A, Lück HJ, Meier W et al (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95:1320-1329
7. Pignata S, De Placido S, Biamonte R et al (2006) Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. BMC Cancer 6:5
8. Pfisterer J, Plante M, Vergote I et al (2006) Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24(29):4699-4707
9. Ferrero JM, Weber B, Geay JF et al (2007) Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann Oncol 18(2):263-268
10. Ten Bokkel Huinik WW,Gore M, Carmichael J et al (1997) Topotecan versus palictaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15:2183-2193
11. Gordon A, Carmichael J, Malfetano J et al (1998) Final analysis of a phase III randomized study of topotecan vs. paclitaxel in advanced epithelial ovarian carcinoma. International Topotecan Study Group. Proc Am Soc Clin Oncol 17:356 Abstract 1374
12. Gore M, ten Bokkel Huinink W, Carmichael J et al (2001) Clinical evidence for topotecan-paclitaxel non-cross-resistance in ovarian cancer. J Clin Oncol 19(7):1893-1900
13. Von Hoff DD, Burris HA, Eckhardt J (1994) Preclinical and phase I trials of topoisomerase I inhibitors. Cancer Chemother Pharmacol 34(Suppl):41-45
14. Kaufmann SH, Peereboom D, Buckwalter CA et al (1996) Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst 88(11):734-741
15. Chou T-C, Motzer, Tong Y et al (1994) Computer quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth. A rational approach to clinical protocol design. J Natl Cancer Inst 86:1517-1524
16. Cheng M-F, Chatterjee S, Berger NA (1994) Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimes. Oncol Res 6:269-279
17. Vecchione F, Fruscio R, Dell'Anna T (2007) A phase II clinical trial of topotecan and carboplatin in patients with newly diagnosed advanced epithelial ovarian cancer. Int J Gynecol Cancer 17(2):367-372
18. National Cancer Institute: Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events v3.0 (CTCAE). http://ctep.cancer.gov/ reporting/ctc_v30.html
19. International Union Against Cancer [UICC]. http://www.uicc.org
20. Rustin GJS, Nelstrop AE, McClean P et al (1996) Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 14:1545-1551
21. Ozols RF, Bundy BN, Greer BE et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21:3194-3200
22. 2 over 3 h) employed in the treatment of gynecologic malignancies. J Cancer Res Clin Oncol 127:55-58
23. Rose PG, Smrekar M, Haba P et al (2005) A phase I/II trial of weekly topotecan and carboplatin in potentially platinum-sensitive relapsed ovarian and peritoneal carcinoma. Gynecol Oncol 99:714-719
24. Simpson AB, Calvert PM, Sludden JA et al (2002) Topotecan in combination with carboplatin: phase I trial evaluation of two treatment schedules. Ann Oncol 13:399-402
25. De Jonge MJ, Loos WJ, Gelderblom H et al (2000) Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects. J Clin Oncol 18:2104-2115
26. Bowman A, Rye T, Ross G et al (2001) Effective dosing of topotecan with carboplatin in relapsed ovarian cancer: a phase I/II study. J Clin Oncol 19(13):3255-3259
27. Markmann M, Kennedy A, Webster K et al (2000) Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer. Gynecol Oncol 79:116-119
28. Bolis G, Scarfone G, Villa A et al (2001) A phase I/II study of topotecan in combination with carboplatin in recurrent epithelial ovarian cancer. Gynecol Oncol 83:477-480
29. Brown JV, Peters WA, Rettenmaier MA et al (2003) Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer. Gynecol Oncol 88(2):136-140
30. Bookman MA, McMeekin DS, Fracasso PM et al (2006) Sequence dependence of hematologic toxicity using carboplatin and topotecan for primary therapy of advanced epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group. Gynecol Oncol 103:473-478
31. Thödtmann R, Kemmerich M, Depenbrock H et al (1998) A clinical phase I trial of topotecan in combination with carboplatin in patients with advanced solid tumors. EORTC 1998; Abstract 263
32. Scarfone G, Parazzini F, Sciatta C et al (2000) A phase I/II study of topotecan in combination with carboplatin in recurrent epithelial ovarian cancer. Ann Oncol 2000; 11 Suppl. 4: Abstract 382P